CYTOSORBENTS CORPORATION (NASDAQ:CTSO) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
|
Submission of Matters to a Vote of Security Holders |
CytoSorbents Corporation (the Company) held its Annual Meeting of
Stockholders (the Annual Meeting) on June 6, 2017. At the Annual
Meeting, the following matters were submitted to a vote of
stockholders:
| 1. |
The election of five (5) directors to serve until the Companys 2018 Annual Meeting of Stockholders, or until their respective successors shall have been duly elected and qualified; |
| 2. |
The approval of an amendment and restatement of the CytoSorbents Corporation 2014 Long-Term Incentive Plan; and |
| 3. |
The ratification of the appointment of WithumSmith Brown, PC as the Companys independent registered public accounting firm for the year ending December 31, 2017. |
At the close of business on April 12, 2017, the record date for
the determination of stockholders entitled to vote at the Annual
Meeting, there were 28,108,382 shares of the Companys Common
Stock outstanding and entitled to vote at the Annual Meeting. The
holders of 20,518,756 shares of the Companys Common Stock were
represented in person or by proxy at the Annual Meeting,
constituting a quorum.
At the Annual Meeting, the five directors were elected, and the
other proposals submitted to stockholders were approved.
Proposal No. 1 Election of Directors
The vote with respect to the election of directors was as
follows:
| Nominees | For | Withheld | Broker Non-Votes | ||||
| Phillip P. Chan | 7,180,752 | 493,954 | 12,844,050 | ||||
| Al W. Kraus | 6,554,788 | 1,119,918 | 12,844,050 | ||||
| Edward R. Jones | 7,328,013 | 346,693 | 12,844,050 | ||||
| Michael G. Bator | 6,874,455 | 800,251 | 12,844,050 | ||||
| Alan D. Sobel | 7,302,263 | 372,443 | 12,844,050 | ||||
Proposal No. 2 Approval of Amendment and Restatement of
CytoSorbents Corporation 2104 Long-Term Incentive Plan
The vote with respect to the proposal to approve an amendment and
restatement of the CytoSorbents Corporation 2014 Long-Term
Incentive Plan was as follows:
| For | Against | Abstain | ||
| 4,987,879 | 2,627,462 | 59,365 |
Proposal No. 3 Ratification of the Appointment of Independent
Registered Public Accounting Firm
The vote with respect to the ratification of the appointment of
WithumSmith Brown PC as the Companys independent registered
public accounting firm for the year ending December 31, 2017 was
as follows:
| For | Against | Abstain | ||||
| 20,082,051 | 282,152 | 154,553 | ||||
About CYTOSORBENTS CORPORATION (NASDAQ:CTSO)
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.
